ArticleAME case reports2025
A case report of hyperammonemic encephalopathy induced by high-dose continuous infusion of 5-fluorouracil in a patient with rectal cancer.
Article in AME case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Recurrent hyperammonemic encephalopathy in a breast cancer patient receiving capecitabine therapy: a case report and literature review.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hyperammonemic encephalopathy caused by high-dose infusion of 5-fluorouracil (5-FU) is a rare adverse reaction in rectal cancer patients with an incidence rate of 5.7%. Although the patient could be restored to normal after supportive treatments, the occurrence of this side effect was still inevitable. Therefore, we analyzed the data of patients during chemotherapy and combined with relevant literature to provide reference for the prevention and treatment of hyperammonia-induced encephalopathy. Case Description: The patient experienced severe consciousness disorders, unresponsive to stimuli, and stiff limbs during two cycles of 5-FU chemotherapy (after 40 hours of infusion), meanwhile the levels of blood ammonia were 117.0 and 349.0 µmol/L, lactate were 9.1 and 7.6 mmol/L respectively. The patient recovered consciousness and all of those laboratory indicators and vital signs turned to be normal through interrupting use of 5-FU and corresponding treatments after approximately 12 hours. Conclusions: Hyperammoniac encephalopathy was hard to prevent, we still recommended to conduct a comprehensive evaluation of the patient's physical condition including nutritional status, liver and kidney function, dihydropyrimidine dehydrogenase (DPD) level before chemotherapy in cases of muscle loss, infection or dehydration. In additional, therapeutic drug monitoring (TDM) can be considered to monitor blood drug concentration and guide the 5-FU dosage if possible. The early consciousness changes of patients during chemotherapy can remind us of prompt detection and treatment to avoid coma or even death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.